FDA Rule Proposal Could Lead to Liability for Generic Drug Manufacturers

The U.S. Food and Drug Administration (FDA) is proposing new rule changes that would permit generic drug manufacturers to amend drug warning labels when they receive new information related to drug safety; irrespective of whether the revised labeling differs from the brand name manufacturer. The proposed rules further provide that the generic manufacturer would be required to submit the labeling changes along with the data supporting the change to the FDA, which would review the request and post the data in a public web page.

To read the rest of this article, authored by Michael P. Luongo, visit Risky Business – Avoiding Product Liability, Commercial, and Other Litigation.

Leave a Reply

Next ArticleNew Jersey Supreme Court Denies Another MultiCounty Litigation Application Without Explanation